Literature DB >> 11180127

Blocking L-selectin and alpha4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease.

B Li1, J Y New, E H Yap, J Lu, S H Chan, H Hu.   

Abstract

L-selectin, LFA-1 and alpha(4) integrins play important roles in the homing of naïve T cells into peripheral lymphoid tissues. L-selectin- or LFA-1-deficient lymphocytes cannot effectively home to lymph nodes (LN), and antibody blockade of alpha(4) integrins also hinders lymphocytes homing. The present study was initiated to explore whether it is feasible to ameliorate acute graft-versus-host disease (aGVHD) by modulating the homing process of donor cells in the recipient in a mouse model. Using a fluorescence labeling method, we found that two monoclonal antibodies directed at L-selectin and alpha(4) integrins, respectively, when used in combination, could delay half of the donor C57BL/6J mouse spleen cells homing into the LN of recipient BALB/c mouse 15 h after injection. Spleen cells (1 x 10(7)) derived from C57BL/6J (H-2(b)) mice were injected into each C.B-17 SCID recipient mouse (H-2(d)) with or without prior incubation with 10 microg each of the two antibodies. T cell repopulation in the blood was observed in both groups of mice at a comparable level 14 days after injection of the donor cells. Eight control mice started to show aGVHD signs 7 - 14 days after the injection, and all died by day 31. However, among the ten mice that received the antibody-treated donor cells, two died before day 29, four survived between 36 and 78 days, and the remaining four survived more than 150 days, with two of them aGVHD free. It is apparent that the temporarily reduced lymphocyte homing into LN reduced the alloreactivity of the donor T cells, thus providing a simple way of modifying aGVHD. This novel approach may shed light on the prevention of aGVHD associated with clinical bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180127

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

2.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

Authors:  Elisha Waldman; Sydney X Lu; Vanessa M Hubbard; Adam A Kochman; Jeffrey M Eng; Theis H Terwey; Stephanie J Muriglan; Theo D Kim; Glenn Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 3.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation.

Authors:  Ines A Silva; Krystyna Olkiewicz; David Askew; Jacquelyn M Fisher; Meghana N Chaudhary; Kevin M Vannella; Daphne T Deurloo; Sung W Choi; Elizabeth M Pierce; Shawn G Clouthier; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-01       Impact factor: 5.742

Review 5.  Leukocyte migration and graft-versus-host disease.

Authors:  Christian A Wysocki; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

6.  Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease.

Authors:  Laurent Burnier; François Saller; Linda Kadi; Anne C Brisset; Rocco Sugamele; Lucie Baudino; Françoise Bono; Jean-Marc Herbert; Peter Carmeliet; Marc Schapira; Shozo Izui; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

7.  L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease.

Authors:  Suparna Dutt; Joerg Ermann; Diane Tseng; Yin Ping Liu; Tracy I George; C Garrison Fathman; Samuel Strober
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Authors:  Britt E Anderson; Patricia A Taylor; Jennifer M McNiff; Dhanpat Jain; Anthony J Demetris; Angela Panoskaltsis-Mortari; Ann Ager; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

9.  Reciprocal function of Galphai2 and Galphai3 in graft-versus-host disease.

Authors:  Yong Zhu Jin; Brian D Thompson; Zho Yan Zhou; Yineng Fu; Lutz Birnbaumer; Mei X Wu
Journal:  Eur J Immunol       Date:  2008-07       Impact factor: 5.532

10.  Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation.

Authors:  Ying-Jun Chang; Xiang-Yu Zhao; Ming-Rui Huo; Xiao-Jun Huang
Journal:  J Clin Immunol       Date:  2009-05-22       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.